Dalton Pharma Services, as a part of a $10 million facility and capital expansion, has invested in a fully automated Sterile Liquid Filling System that will become operational in 1Q19. The new fill line allows larger batch sizes (~40 BPM), a broader range of filling volumes and container closure systems. It also provides nitrogen purging and individual bottle serialization.
 
This investment is part of Dalton’s continued facility and service improvements to help shorten lead times and scale up for clients from clinical batches to small scale commercial production.
 
“The flexibility and aseptic assurance that this new fill-line provides will enable Dalton to extend services beyond the current clinical stage and accelerate the development of clients` sterile drug products to reach the market, faster.” said Peter Pekos, chief executive officer and president, Dalton Pharma Services.